11
To review the milestones in the nearly 120-year history of
CSL Behring, please see Figure 3.
From these beginnings until the present, CSL Behring has
continued to play a leading role in the development of life-
saving therapies. Today, CSL Behring is a global company
withmore than 9,000 employees inmore than 20 countries.
Headquartered in King of Prussia, Pennsylvania, USA, its
research and manufacturing facilities produce more than
30 different brands of plasma-based products worldwide.
2000
2010
1993
Berinert
®
becomes
available in
Switzerland
1991
Behringwerke Iicenses
the first intramuscular
immunoglobulin
with a dedicated
virus inactivation step
(pasteurization)
2008
The first proline-
stabilized intravenous
immunoglobulin
launches in the United
States and Europe
2007
I.M.P.A.C.T. clinical
study completed
2007
ZLB Behring changes
name to CSL Behring
2007
Mix2Vial
™
introduced, in
many countries,
simplifying administration
of Berinert
®
2006
CSL Behring introduces the first
subcutaneous immunoglobulin
in the United States
2006
websites launch
2004
CSL acquires Aventis
Behring to form
ZLB Behring
1996
Armour
Pharmaceuticals
and Behringwerke
are merged to
form Centeon,
later to become
Aventis Behring
2000
CSL acquires ZLB
to form ZLB
Bioplasma
1997
Berinert
®
is licensed
in Hungary
2003
Berinert
®
becomes
available in Argentina
2005
ZLB Behring initiates
I.M.P.A.C.T., the
largest, controlled
clinical trial of
HAE treatment
1990
Berinert
®
is licensed in
Austria and Japan, and
becomes available on
a named-patient basis in
many other countries
2009
Berinert
®
launches in
the United States and
numerous European
countries
2013
Berinert
®
receives
approval for pre-
procedure prevention
in Europe (short-term
prophylaxis,
e.g. before surgery)
2011
Berinert
®
receives
approval for self-
administration and the
introduction of virus
filtration (nanofiltration)
2010
Berinert
®
is licensed
in Australia and
Canada
Water
Blue sideof the adapter
Integrated filter
Concentrate adapter
Concentrate
CSL Behring
